Insulin/insulin suspension isophane biosimilar - Wockhardt

Drug Profile

Insulin/insulin suspension isophane biosimilar - Wockhardt

Alternative Names: Biphasic insulin isophane biosimilar - Wockhardt; Insulin suspension isophane/insulin biosimilar - Wockhardt; Recombinant (r-DNA) human insulin biphasic - Wockhardt; Wosulin 30/70; Wosulin 50/50

Latest Information Update: 01 Mar 2016

Price : $50

At a glance

  • Originator Wockhardt
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus

Most Recent Events

  • 21 Aug 2013 Wockhardt terminates a phase III trial in Type 1 diabetes mellitus in USA and India (NCT01308437)
  • 01 Mar 2011 Phase-III clinical trials in Type-1 diabetes mellitus in USA (SC)
  • 01 Jan 2011 Phase-I clinical trials for Type-1 diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top